Ignite Creation Date:
2024-05-06 @ 8:53 AM
Last Modification Date:
2024-10-26 @ 12:06 PM
Study NCT ID:
NCT02841215
Status:
COMPLETED
Last Update Posted:
2023-09-22
First Post:
2016-06-30
Brief Title:
Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
A Randomized Controlled Double-blind Trial Assessing the Efficacy of a 400µgkg Ivermectin 5 Permethrin Emollient Cream Regimen in Patients With Crusted Scabies as Compared to a 200µgkg Ivermectin 5 Permethrin Emollient Cream Regimen
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GALECRUSTED
Brief Summary:
Severe forms of scabies crusted scabies and profuse scabies require a specific treatment Ivermectin is a recommended treatment in common forms of scabies and represents a promising treatment in crusted scabies in case reports However response to ivermectin remains variable among studies and there is no consensus on the schemes to adopt dosages and administrations Ivermectin at 400 µgkg has already been used without showing toxicity in head lice treatment in particular Investigators propose to demonstrate that 400µgkg ivermectin dosage will show better efficacy than a 200µgkg in patients with severe forms of scabies crusted and profuse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None